Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort.
Illini O, Hund AC, Kopp HG, Moskovitz M, Mountzios G, Brueckl WM, Früh M, Leßmann ME, Christopoulos P, Stenzinger A, Thomas M, Gillis R, Peled N, Acker F, Addeo A, Charpidou A, Grohé C, Mauti L, Rothschild SI, Schmid S, Schumann C, Urban D, Wurm R, Ekman S, Skribek M, Glanemann F, Wiesweg M, Ackermann CJ, Agelaki S, Hoffknecht P, Jakopović M, Kern J, König D, Kostenzer K, Kropf-Sanchen C, Laack E, Lang D, Nagl L, Pall G, Reck M, Kian W, Allemann AT, Alt J, Araújo D, Bokas A, Hannah F, Julie KJ, Weinlinger C, de Langen AJ, Fergadis EG, Fountzilas E, Froesch P, Frost N, Griesinger F, Jordan F, Karanikiotis C, Kiesewetter B, Korantzis I, Machado AL, Economopoulou P, Pilz A, Reimann P, Rittmeyer A, Saad A, Samitas K, Schulmann K, Shah R, Stratmann JA, Taghizadeh H, Tammoscheit K, Tufman A, Weber JP, Wöll E, Valipour A, Overbeck TR, Hochmair MJ.
Illini O, et al. Among authors: kiesewetter b.
J Thorac Oncol. 2026 Feb 24:103651. doi: 10.1016/j.jtho.2026.103651. Online ahead of print.
J Thorac Oncol. 2026.
PMID: 41747890
Free article.
